Schroder Investment Management Group Grows Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Schroder Investment Management Group lifted its position in Boston Scientific Co. (NYSE:BSX) by 20.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 7,482,062 shares of the medical equipment provider’s stock after purchasing an additional 1,281,005 shares during the quarter. Boston Scientific makes up 0.6% of Schroder Investment Management Group’s holdings, making the stock its 29th biggest holding. Schroder Investment Management Group’s holdings in Boston Scientific were worth $668,298,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of BSX. D.A. Davidson & CO. raised its stake in shares of Boston Scientific by 3.2% during the third quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider’s stock worth $917,000 after acquiring an additional 342 shares in the last quarter. Townsquare Capital LLC raised its position in Boston Scientific by 191.9% in the 3rd quarter. Townsquare Capital LLC now owns 26,896 shares of the medical equipment provider’s stock worth $2,254,000 after purchasing an additional 17,683 shares during the period. Glenmede Trust Co. NA lifted its stake in Boston Scientific by 19.0% in the third quarter. Glenmede Trust Co. NA now owns 20,463 shares of the medical equipment provider’s stock worth $1,715,000 after purchasing an additional 3,261 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Boston Scientific during the third quarter valued at about $6,254,000. Finally, CreativeOne Wealth LLC increased its holdings in shares of Boston Scientific by 62.0% in the third quarter. CreativeOne Wealth LLC now owns 4,478 shares of the medical equipment provider’s stock worth $375,000 after buying an additional 1,714 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of BSX opened at $99.29 on Friday. Boston Scientific Co. has a 52 week low of $66.80 and a 52 week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market cap of $146.86 billion, a P/E ratio of 79.43, a P/E/G ratio of 2.79 and a beta of 0.77. The business’s 50 day moving average price is $102.16 and its 200-day moving average price is $93.11.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent analyst reports. Canaccord Genuity Group raised their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Argus set a $130.00 price target on Boston Scientific in a report on Tuesday, February 18th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Morgan Stanley upped their target price on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $108.91.

Insiders Place Their Bets

In related news, EVP John Bradley Sorenson sold 4,119 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares in the company, valued at $3,179,416.38. The trade was a 10.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the sale, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 137,302 shares of company stock valued at $14,319,269. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.